Friday, 23 July 2021 09:31 GMT

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013


( MENAFN - GlobeNewsWire - Nasdaq BE)ND, Ore., July 22, 2021 (GLOBE NEWSWIRE) --

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1) Stonepine Capital, L.P.
Company dealt in Strongbridge Biopharma plc
Class of relevant security to which the dealings being disclosed relate (Note 2) Ordinary Shares
Date of dealing Purchase - 21/07/2021

2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long Short
Number (%)
Number (%)
(1) Relevant securities 4,091,221 6.037% 0
(2) Derivatives (other than options) 0 0
(3) Options and agreements to purchase/sell 0 0
Total 4,092,221 6.037% 0

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities N/A N/A
(2) Derivatives (other than options) N/A N/A
(3) Options and agreements to purchase/sell N/A N/A
Total N/A N/A

Ap20

1. DEALINGS (Note 4)
(a) Purchases and sales

Purchase/sale Number of relevant securities Price per unit (Note 5)
Purchase
167,693 $ 2.7436

(b) Derivatives transactions (other than options transactions)

Product name,
e.g. CFD
Nature of transaction
(Note 6)
Number of relevant securities
(Note 7)
Price per unit
(Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name,
e.g. call option
Writing, selling,
purchasing,
varying etc.
Number of securities
to which the option
relates (Note 7)
Exercise
price
Type, e.g.
American,
European etc.
Expiry
date
Option money
paid/received
per unit (Note 5)

(ii) Exercising

Product name,
e.g. call option
Number of securities Exercise price per
unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction
(Note 8)
Details Price per unit
(if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None

 

Is a Supplemental Form 8 attached? (Note 9) NO


Date of disclosure 22 July 2021
Contact name Jeff Nunnenkamp
Telephone number +1 541-647-5673
If a connected EFM, name of offeree/offeror with which connected N/A
If a connected EFM, state nature of connection (Note 10) N/A

MENAFN22072021004107003653ID1102493612


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.